Respiratory Disease in the Netherlands

Introduction

The IRC, a coalition of respiratory clinicians, patients and industry partners, aims to transform post-pandemic respiratory care and reduce mortality by a third globally by 2030 - in line with the UN Sustainable Development Goals.

The IRC is calling on governments and policy makers to establish funded national strategies, which include prevention, new models of care, ambitious measurable targets, and accountable leadership to improve lung health by focusing on:

Better...

1. Prevention of respiratory diseases
2. Access to the right treatment at the right time
3. Action on reducing inequalities
4. Prioritisation of research, data and insight to improve care

In The Netherlands organisations in the field of respiratory diseases cooperate together within the Lung Alliance Netherlands to achieve synergy and better research, prevention and care.

The IRC welcomes the work on this initiative and is also committed to collaborating with all relevant stakeholders in promoting lung health across The Netherlands by developing national strategies.

Societal economic cost by disease:

- Asthma: €2.5 billion
- COPD: €10.5 billion
- Interstitial Lung Disease: €5.7 billion
- Lower Respiratory Tract Infections: €3.3 billion
- Mesothelioma: €85.9 billion
- Lung Cancer: €12.5 billion
- Tuberculosis: €83.9 million
- Mesothelioma: €585.9 million
- Tuberculosis: €637.1 thousand
- Interstitial Lung Disease: €51.7 billion

This initiative is made possible with the contributions of the partner organisations who all support the IRC’s goals: Expertise and time were provided by the European Respiratory Society, European Lung Foundation and Global Allergy and Airways Patient Platform; funding, expertise and time were contributed by AstraZeneca, Chiesi Group, GSK, Moderna, Amgen, Sanofi and Regeneron; additional funding was provided by Boehringer Ingelheim.

Data taken from IRC Lung Facts https://international-respiratory-coalition.org/lung-facts/diseases/